- Zacks Small Cap Research•2 months ago
The company did not record any revenues during the three months ended March 31, 2015. The increase was primarily due to costs associated with preparations of the CF101 Phase III studies in the treatment of rheumatoid arthritis and psoriasis. In September, 2015, the company closed a registered direct offering with institutional investors for gross proceeds of $9 million.
- Insider Monkey•4 months ago
U.S stocks are enjoying a strong day today as the U.S. dollar declines to its lowest levels in eight months and commodity prices rise. Among the most notable stocks making upward moves today are Chesapeake Energy Corporation (NYSE:CHK), Vale SA (ADR) (NYSE:VALE), Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF), Cliffs Natural Resources Inc (NYSE:CLF), and Barclays PLC […]
|Bid||2.02 x 800|
|Ask||2.64 x 1000|
|52wk Range||1.46 - 7.85|
|Day's Range||2.06 - 2.11|
|Avg Vol (3m)||95,965|
As of 4:00 PM EDT. Market closed.